<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> have an increased risk of developing oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>; surveillance is therefore recommended for these patients </plain></SENT>
<SENT sid="1" pm="."><plain>However, it has never been proven that Barrett surveillance is actually effective </plain></SENT>
<SENT sid="2" pm="."><plain>A recent article in The American Journal of Gastroenterology shows that patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> had a lower risk of developing oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> when they had previous surveillance or endoscopic therapy </plain></SENT>
<SENT sid="3" pm="."><plain>These results suggest that surveillance may improve survival of patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, there is no convincing evidence that surveillance has an effect on mortality due to oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Although the absolute overall risk of developing oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is low, surveillance is important in the small group of patients with a high risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
</text></document>